Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Tumour Biol ; 37(7): 8753-64, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26743778

RESUMEN

Leonurus sibiricus L. is a traditional medicinal plant which occurs in southern Siberia, China, Korea, Japan, and Vietnam. The plant shows several pharmacological effects, but the most interesting is its anti-cancer activity. The aim of our study was to examine the induction of apoptosis in malignant glioma cells, the most aggressive primary brain tumors of the central nervous system, following treatment with transformed root (TR) or non-transformed root (NR) L. sibiricus extracts. Both the NR and TR extracts were found to have cytotoxic activity in the glioma primary cells. The human glioblastoma cell lines obtained from patients were confirmed to be tumorogenic by the following three markers: D10S1709, D10S1172, and D22S283. HPLC and MS analysis revealed the presence of polyphenolic compounds (chlorogenic acid, ferulic acid, caffeic acid, p-coumaric acid, ellagic acid, and verbascoside) in both sets of root extracts. In summary, our findings demonstrate that treatment of the glioma cells with NR and TR extracts resulted (a) in significant cell growth inhibition, (b) S- and G2/M-phase cell cycle arrest, and (c) apoptosis in a dose-dependent fashion by changing Bax/Bcl-2 ratio (about 4-fold increase) and p53 (5-fold increase) activation. These findings indicate that NR and TR extracts exhibit anti-cancer activity through the regulation of genes involved in apoptosis. This is the first report to demonstrate the cytotoxic effect of polyphenolic extracts from L. sibiricus roots against glioma cells, but further studies are required to understand the complete mechanism of its apoptosic activity.


Asunto(s)
Apoptosis/efectos de los fármacos , Glioma/tratamiento farmacológico , Leonurus/química , Raíces de Plantas/química , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Proteína X Asociada a bcl-2/metabolismo , Antineoplásicos/química , Antineoplásicos/farmacología , Biomarcadores de Tumor/metabolismo , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/metabolismo , Carcinogénesis/efectos de los fármacos , Puntos de Control del Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Glioma/metabolismo , Humanos , Persona de Mediana Edad , Extractos Vegetales/farmacología , Plantas Medicinales/química , Polifenoles/química , Polifenoles/farmacología
2.
J Neurooncol ; 102(3): 395-407, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-20803305

RESUMEN

Glioblastoma cell cultures in vitro are frequently used for investigations on the biology of tumors or new therapeutic approaches. Recent reports have emphasized the importance of cell culture type for maintenance of tumor original features. Nevertheless, the ability of GBM cells to preserve EGFR overdosage in vitro remains controversial. Our experimental approach was based on quantitative analysis of EGFR gene dosage in vitro both at DNA and mRNA level. Real-time PCR data were verified with a FISH method allowing for a distinction between EGFR amplification and polysomy 7. We demonstrated that EGFR amplification accompanied by EGFRwt overexpression was maintained in spheroids, but these phenomena were gradually lost in adherent culture. We noticed a rapid decrease of EGFR overdosage already at the initial stage of cell culture establishment. In contrast to EGFR amplification, the maintenance of polysomy 7 resulted in EGFR locus gain and stabilization even in long-term adherent culture in serum presence. Surprisingly, the EGFRwt expression pattern did not reflect the latter phenomenon and we observed no overexpression of the tested gene. Moreover, quantitative analysis demonstrated that expression of the truncated variant of receptor-EGFRvIII was preserved in GBM-derived spheroids at a level comparable to the initial tumor tissue. Our findings are especially important in the light of research using glioblastoma culture as the experimental model for testing novel EGFR-targeted therapeutics in vitro, with special emphasis on the most common mutated form of receptor-EGFRvIII.


Asunto(s)
Neoplasias Encefálicas/patología , Receptores ErbB/metabolismo , Glioblastoma/patología , Animales , Bromodesoxiuridina/metabolismo , Adhesión Celular/fisiología , Ciclo Celular/fisiología , Proliferación Celular , Receptores ErbB/genética , Regulación Neoplásica de la Expresión Génica/genética , Humanos , Modelos Animales , ARN Mensajero/metabolismo , Factores de Transcripción SOXB1/metabolismo , Esferoides Celulares/patología , Factores de Tiempo , Células Tumorales Cultivadas
3.
Folia Neuropathol ; 48(3): 212-6, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20925006

RESUMEN

Authors present a case of a 57-year-old woman with primary spinal cord malignant melanoma. Intramedullary localization of primary melanoma is extremely rare. The patient presented neurological deficits such as lower limbs paresis and sensory loss. MRI examination showed intramedullar tumor located on the Th10 vertebra level. Surgical treatment with total removal of tumor was performed. Histopathological study confirmed melanoma. Subsequent chemotherapy was given. Tumor was successfully treated by neurosurgery; radio- and chemotherapy with disease free follow up of 9 months. Surgical treatment of melanoma in this location is extremely important as it leads to regression of neurological symptoms and improvement of the quality of life.


Asunto(s)
Melanoma/patología , Paresia/patología , Neoplasias de la Médula Espinal/patología , Terapia Combinada , Femenino , Humanos , Melanoma/complicaciones , Melanoma/tratamiento farmacológico , Melanoma/cirugía , Persona de Mediana Edad , Paresia/tratamiento farmacológico , Paresia/etiología , Paresia/cirugía , Médula Espinal/patología , Médula Espinal/cirugía , Neoplasias de la Médula Espinal/complicaciones , Neoplasias de la Médula Espinal/tratamiento farmacológico , Neoplasias de la Médula Espinal/cirugía , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA